Patents, Data Exclusivity, and the Development of New Drugs

51 Pages Posted: 17 Jun 2019 Last revised: 26 Jun 2019

See all articles by Fabian Gaessler

Fabian Gaessler

Max Planck Institute for Innovation and Competition

Stefan Wagner

ESMT European School of Management and Technology

Date Written: June 24, 2019

Abstract

Pharmaceutical firms typically enjoy market exclusivity for new drugs from concurrent protection of the underlying invention (through patents) and the clinical trials data submitted for market approval (through data exclusivity). Patent invalidation during drug development renders data exclusivity the sole source of protection and shifts the period of market exclusivity at the project level. Patent invalidation therefore constitutes a natural experiment that allows us to causally identify how the duration of market exclusivity affects firms' incentives to innovate. In instrumental variables regressions we quantify the effect of a one-year reduction in expected market exclusivity on the likelihood of drug commercialization. We provide first estimates of the responsiveness of R&D investments to market exclusivity expectations and hereby inform the ongoing policy debate on the regulation of intellectual property rights in the pharmaceutical industry.

Keywords: patents, drugs, data exclusivity, clinical trials

JEL Classification: K41, L24, L65, O31, O32, O34

Suggested Citation

Gaessler, Fabian and Wagner, Stefan, Patents, Data Exclusivity, and the Development of New Drugs (June 24, 2019). Available at SSRN: https://ssrn.com/abstract=3401226 or http://dx.doi.org/10.2139/ssrn.3401226

Fabian Gaessler (Contact Author)

Max Planck Institute for Innovation and Competition ( email )

Marstallplatz 1
Munich, 80539
Germany

Stefan Wagner

ESMT European School of Management and Technology ( email )

Schlossplatz 1
10117 Berlin
Germany

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
165
Abstract Views
832
rank
203,211
PlumX Metrics